Hofseth Biocare ASA: PROXY RIGHTS AT GENERAL MEETING
04 December 2020 - 2:21AM
Hofseth Biocare ASA: PROXY RIGHTS AT GENERAL MEETING
Ola Holen, chairman of the Board of Hofseth BioCare ASA (the
"Company" or "HBC"), has in connection to the upcoming
extraordinary general meeting on 4 December 2020, received proxy
rights with voting instructions in favour of the suggested
resolutions from shareholders representing 256,942,508 shares in
the Company, equal to approx. 72.4 % of the voting rights.
Mr. Holen owns as of the date hereof a total of 1,465,253
shares, equal to 0.41 per cent of the outstanding shares in HBC.
935,388 shares are owned via his fully owned company, Paso AS, and
529,865 shares are held privately.
After the receipt of the above-mentioned proxies, Mr. Holen
represents a total of 258,407,761 shares and votes, equal to 72.81
% of the voting rights at the upcoming extraordinary general
meeting in HBC on 4 December 2020.
For further information, please contact:Jon Olav Ødegård, CFO of
Hofseth BioCare ASAMob: +47 93632966E-mail:
joo@hofsethbiocare.no
About Hofseth BioCare ASA:HBC is a Norwegian biotech company
that develops high-value ingredients and finished products
currently targeting the consumer health market. Research is ongoing
to identify the individual elements within the products that
modulate inflammation and the immune response with pre-clinical
studies in multiple clinics and university research labs in several
countries. Lead clinical and pre-clinical candidates are in
development for the protection of the Gastro-Intestinal (GI) system
against inflammation, including ulcerative colitis and the orphan
condition necrotising enterocolitis, as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron
Deficiency Anemia, all using peptide fractions of Salmon Protein
Hydrolysate. Preclinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD
(“smokers lung”) as well as clinical work in COVID.The company is
founded on the core values of sustainability, traceability and
optimal utilization of natural resources. Through an innovative
hydrolysis technology, HBC can preserve the quality of lipids,
proteins and collagen-calcium from fresh salmon off-cuts. Hofseth
BioCare's headquarters are in Ålesund, Norway with branches in
Oslo, London, Zürich, Chicago, Menlo Park and Tokyo.HBC is listed
on Euronext Expand Oslo with ticker "HBC". More information about
Hofseth BioCare at hofsethbiocare.com and
facebook.com/hofsethbiocare
This information is subject to the disclosure requirements
pursuant to Section 5-12 of the Norwegian Securities Trading
Act